Lung disorder

This early-stage trial tests a personalized cancer vaccine for people with bladder or stomach cancer who still have tiny amounts of cancer DNA in their blood after surgery. The vaccine is made from unique proteins in each person's tumor and aims to train the immune system to find…

This study tests a new vaccine called rF1V-1018 to prevent pneumonic plague, a severe lung infection spread by aerosol. Researchers will give the vaccine to 148 healthy adults aged 18 to 55 to check if it triggers a strong immune response and is safe. The goal is to find the best…

This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) against a placebo in 56 people with COPD and lung hyperinflation. The goal is to see if the inhaler improves both lung function and heart function, measured by MRI. Participants will receiv…

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This phase III trial compares adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in adults aged 70+ with advanced non-small cell lung cancer. The goal is to see if the combination improves survival. About 304 participants will be enrolled.

This study tests a new combination of two drugs (trastuzumab deruxtecan and pembrolizumab) against standard chemotherapy plus pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of HER2 and low PD-L1. About 686 adults will t…

This study tests whether adding a precise type of radiation therapy (I²-PORT) after lung cancer surgery can help prevent the cancer from coming back. Participants have non-small cell lung cancer with remaining cancer in lymph nodes after initial treatment. The trial compares stan…

This early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…

This study looks at the long-term safety of an inhaled drug (AP01) for people with progressive lung scarring (pulmonary fibrosis). It is for those who already completed an earlier Avalyn Pharma study. About 340 participants will receive the drug and be monitored for side effects …

This Phase 2 trial tests an experimental inhaled medication called LTI-03 in about 120 people with idiopathic pulmonary fibrosis (IPF), a progressive lung disease that causes scarring and breathing difficulty. Participants will inhale LTI-03 or a placebo twice daily for 24 weeks.…

This study tests whether adding radiation therapy to the usual maintenance drug atezolizumab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 138 participants who have already responded to initial chemo-immunotherapy will be…

This study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The goal is to see if the treatment is safe and works against these cancers. About 360 participants will take part in this early-s…

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy after surgery can help prevent non-small cell lung cancer from coming back. About 1,210 people with stage II to IIIB lung cancer will receive either chemo plus pembrolizumab toge…

This study compares two common antibiotics, azithromycin and doxycycline, in adults hospitalized with community-acquired pneumonia who are also receiving a beta-lactam antibiotic. The goal is to see which combination helps patients leave the hospital sooner and reduces the need f…

This study tests a new drug called ALE.P03 in adults with advanced or metastatic solid tumors that have a specific protein (Claudin-1) on their surface. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial has two phases: …

This study looks at the long-term safety of the drug astegolimab in people with chronic obstructive pulmonary disease (COPD). It includes about 2,000 participants who already completed a one-year study with the drug. The main goal is to track any side effects that may occur with …

This study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy (durvalumab) can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. The trial involves 60 adults with operable stage I…

This early-phase study tests two cancer drugs—lenvatinib (a daily pill) and pembrolizumab (an IV infusion)—in 20 adults with HPV-related recurrent respiratory papillomatosis (RRP) that has spread to the lungs. The goal is to see if the combination can shrink papillomas and reduce…

This early-stage trial is testing an experimental drug called BMS-986488, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 437 adults w…

This phase 1 trial tests a new drug called AWT020, given alone or with other cancer treatments, in people with advanced solid tumors such as non-small cell lung cancer, colorectal cancer, kidney cancer, and melanoma. The main goals are to check the drug's safety, find the best do…

This study tests a new drug called ABBV-706 combined with the immunotherapy atezolizumab as a first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 180 adults will receive either the new combination at one of two dose…

This study tests an experimental drug called AZD0292 in 435 people aged 12 and older who have bronchiectasis and a long-term lung infection with Pseudomonas aeruginosa. The goal is to see if the drug can reduce the number of moderate-to-severe lung flare-ups compared to a placebo…

This phase 3 trial is testing whether the immunotherapy drug durvalumab, given after surgery, can prevent early-stage non-small cell lung cancer from coming back. About 306 participants who have had their tumor completely removed will be randomly assigned to receive durvalumab or…

This phase III trial is testing whether giving chemotherapy and immunotherapy both before and after surgery (perioperative) is better than giving it only after surgery (adjuvant) for people with stage II-IIIB non-small cell lung cancer that can be removed. About 1,100 participant…

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…

This Phase III trial is testing whether adding bevacizumab to the standard drug osimertinib can better control advanced EGFR-mutant non-small cell lung cancer. About 300 people with stage IIIB or IV disease will be randomly assigned to receive either the combination or osimertini…

This study tests a new drug called GSK3862995B in 446 adults with bronchiectasis, a long-term lung condition. The goal is to see if the drug can reduce the number of serious lung infections (exacerbations) compared to a placebo. Participants will receive either one of two doses o…

This study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.

This study tests a new drug, firmonertinib, against two standard treatments for people with advanced non-small-cell lung cancer that has certain rare genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease will be random…

This phase 3 trial tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer compared to pembrolizumab alone. The study enrolls about 614 adults whose tumors have high PD-L1 lev…

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This study tests a temporary device that stimulates the diaphragm (the main breathing muscle) in ICU patients on breathing machines. The goal is to see if it helps patients breathe more on their own and recover from lung injury. About 30 adults with severe breathing failure will …

This phase III trial is testing whether a precise, high-dose radiation technique called stereotactic radiosurgery (SRS) is better at preserving memory and thinking than the current standard of whole brain radiation that avoids the hippocampus (the brain's memory center) plus a dr…

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …

This phase 3 trial tests a new antiviral pill, ibuzatrelvir, alone or with an IV drug (remdesivir) in 300 adults with weak immune systems who have mild-to-moderate COVID-19. The goal is to see if the combination prevents hospitalizations or worsening symptoms better than remdesiv…

This phase III trial is testing whether the immunotherapy drug atezolizumab, given after surgery, can prevent stage I non-small cell lung cancer from returning. About 336 patients who have had their tumor completely removed will be randomly assigned to receive either atezolizumab…

This study tests whether adding two immunotherapy drugs (tislelizumab and surufatinib) to standard chemoradiation can help people with stage III non-small cell lung cancer that cannot be surgically removed. About 160 participants will be randomly assigned to receive either the tw…

This study tests whether adding the experimental drug visugromab to standard chemotherapy and immunotherapy can shrink tumors better than standard treatment alone in people with advanced non-squamous lung cancer that has not been treated before. About 107 adults with newly diagno…

This trial tests a real-time algorithm-driven system that gives doctors feedback on ventilator settings to protect the lungs of critically ill patients. The study will include 208 adults on breathing machines with acute respiratory distress syndrome (ARDS). The goal is to see if …

This study tests whether a new drug called BNT327, combined with standard chemotherapy, helps people with advanced small-cell lung cancer live longer compared to another approved drug (atezolizumab) plus the same chemo. About 621 adults who have not yet been treated for their can…

This phase 3 trial compares a new targeted drug, datopotamab deruxtecan (Dato-DXd), against the standard chemotherapy docetaxel in 400 people with advanced or metastatic non-squamous non-small cell lung cancer that lacks certain gene mutations. The goal is to see if Dato-DXd can …

This early-phase study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…

This study tests a new drug called BMS-986507, alone or with other cancer medicines, in adults with advanced lung or breast cancer that has spread. The goal is to check safety, side effects, and how well the drugs work. About 416 participants will receive different combinations t…

This early-stage trial is testing a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors that have a specific BRAF gene change. The drug is given alone or combined with other medicines like binimetinib or cetuximab. The study aims to find safe doses …

This Phase 3 trial tests a new drug called SYS6010 against standard chemotherapy in 380 people with a specific type of advanced lung cancer (EGFR-mutated) that has stopped responding to targeted therapy. The goal is to see if SYS6010 can delay cancer growth better than chemo. Par…

This study tests a new drug, BNT327, combined with chemotherapy and other agents in people with advanced non-small cell lung cancer who have not had prior treatment. The trial will enroll about 1,260 participants across multiple sites worldwide. The goal is to see if the combinat…

This study tests several new drug combinations in people with advanced non-small cell lung cancer that has spread. The goal is to see if these combinations are safe and can shrink tumors. About 278 adults will take part across 10 countries. The study is open to those with a speci…

This study tests a new drug called EP0031 in people with advanced cancers that have a specific genetic change (RET alteration), including non-small cell lung cancer. The trial has two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. About 265 adult…

This phase 2 trial tests an oral drug called PIPE-791 in 324 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants take either a low or high dose of PIPE-791 or a placebo daily for several months. The main goal is t…

This study tests a new oral drug, BAY 2927088, for people with advanced non-small cell lung cancer that has specific EGFR or HER2 mutations. The trial has four parts to find the safest dose and see if the drug shrinks tumors. About 400 participants will take the drug daily until …

This study tests a drug called H01 (hymecromone) in adults with interstitial lung disease, a condition that causes lung scarring and makes breathing hard. The goal is to see if H01 can lower a marker of lung damage and improve lung function. Participants take the drug as a tablet…

This study tests a new drug, BBT002, in healthy volunteers and people with chronic obstructive pulmonary disease (COPD) or chronic rhinosinusitis with nasal polyps (CRSwNP). The trial is double-blind and placebo-controlled, meaning some participants get the drug and some get a du…

This study tests an oral medication called ibuzatrelvir in adults and teens with COVID-19 who are not hospitalized but have a high risk of becoming severely ill. Participants will receive either the drug or a placebo for 5 days, and researchers will track whether it reduces emerg…

This early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This trial compares oral nicotine pouches (like ZYN) with standard nicotine replacement therapy (patches and lozenges) to help smokers in rural Appalachia reduce or stop cigarette use. The goal is to lower the high rates of lung and oral cancers linked to smoking in this region. …

This early-phase study tests a new drug called SLV-154 in about 70 people with advanced solid tumors (like head and neck, lung, breast, or ovarian cancer) that have spread. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs …

This study tests a new drug called telisotuzumab adizutecan (ABBV-400) combined with an immunotherapy drug (budigalimab or pembrolizumab) in people with advanced non-squamous lung cancer who have not had prior treatment. The goal is to find the best dose that is safe and effectiv…

This study tests a new drug, setidegrasib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if setidegrasib can keep the cancer from growing longer and help people live longer…

This early study will test a personalized mRNA vaccine (RGL-270) given together with standard immunotherapy drugs in 40 people with advanced non-small cell lung cancer. The vaccine is custom-made to target unique markers on each person's tumor. The main goal is to check safety an…

This phase 3 trial is testing a new combination of drugs (BMS-986489) plus chemotherapy against a standard treatment (atezolizumab plus chemotherapy) for people with extensive-stage small cell lung cancer, a fast-growing cancer. The study aims to see if the new combo helps people…

This study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…

This trial investigates whether adding papaverine—a drug traditionally used as a muscle relaxant—to standard chemoradiation can improve treatment for people with stage II to III non-small cell lung cancer. Papaverine targets the energy factories inside cancer cells (mitochondria)…

This study is testing new drugs called RAS(ON) inhibitors for people with advanced non-small cell lung cancer that has a RAS mutation. The goal is to see if these drugs are safe and can shrink tumors or slow the cancer's growth. About 616 adults who have already tried standard tr…

This study tests a new drug called ivonescimab, given with standard chemotherapy, for people with extensive-stage small cell lung cancer who haven't had treatment yet. Ivonescimab is a special antibody that helps the immune system fight cancer and may also block blood vessels tha…

This study tests a new drug called ALE.P02 in people with advanced squamous cell cancers of the lung, head and neck, cervix, or esophagus that have spread or cannot be removed. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 170 adult…

This study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …

This Phase 3 trial tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemo-immunotherapy improves survival in people with metastatic squamous non-small cell lung cancer. About 851 participants will receive pembrolizumab plus chemotherapy, then either…

This study tests a new drug called rilvegostomig against the standard drug pembrolizumab, both given with chemotherapy, as a first treatment for people with advanced non-squamous lung cancer that has spread. About 878 adults whose tumors have a specific protein (PD-L1) will take …

This phase 2 trial is testing three different doses of an investigational drug called telisotuzumab vedotin in about 150 adults with a specific type of advanced lung cancer (non-small cell lung cancer that has high levels of a protein called c-Met and no EGFR mutation). The drug …

This early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …

This study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can help prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and imm…

This study tests whether a personalized breathing machine strategy can improve survival in people with acute respiratory distress syndrome (ARDS), a severe lung condition. About 1,100 adults on ventilators will be randomly assigned to either standard care or a precision approach …

This study tests whether combining experimental RAS(ON) inhibitors with ivonescimab (an immunotherapy) can shrink or control advanced solid tumors that have a RAS mutation. About 370 adults with cancers like non-small cell lung cancer or colorectal cancer will receive these drugs…

This early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body proce…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This study follows 1,400 adults with moderate to severe COPD who are starting Breztri/Trixeo, a triple-combination inhaler. Researchers will track changes in symptoms and quality of life over 12 months in real-world clinics across Latin America, Asia, and the Middle East & Africa…

This phase 3 trial tests whether adjusting the flow rate of high-flow oxygen therapy based on lung volume measurements from a depth camera can reduce the need for intubation in intensive care patients with hypoxemic respiratory failure. About 406 participants will be randomly ass…

This early-stage study tests a personalized radiation technique called PULSAR for lung cancers located near the center of the chest. The goal is to make treatment safer while still effectively controlling the tumor. About 30 adults with primary or metastatic lung cancer will rece…

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or stopped responding to standard therapy. OBX-115 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This Phase 3 trial tests an oral drug called belumosudil in adults who have chronic lung allograft dysfunction (CLAD) after a bilateral lung transplant. CLAD is a form of chronic rejection that slowly worsens lung function. The study compares belumosudil to a placebo, both given …

This study tests an inhaled medicine called L606 for people with high blood pressure in the lungs due to lung disease. About 344 adults will be randomly assigned to receive L606 or a placebo. The main goal is to see if L606 helps them walk farther in six minutes and delays worsen…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This Phase 2 trial tests whether adding a personalized mRNA vaccine (V940) to standard pembrolizumab and chemotherapy helps people with newly diagnosed metastatic squamous non-small cell lung cancer live longer and keep the cancer from growing. About 180 participants will receive…

This phase 3 study compares the experimental drug pumitamig to the standard treatment durvalumab in people with stage III lung cancer that cannot be removed by surgery. Participants must have finished chemoradiation without their cancer getting worse. The main goal is to see if p…

This study tests whether adding an experimental mRNA vaccine (V940) to the immunotherapy drug pembrolizumab (Keytruda) can keep lung cancer from returning after surgery. It includes 680 people with stage II to IIIB non-small cell lung cancer whose tumors did not fully respond to …

This study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, alone or with standard chemotherapy and immunotherapy, for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 170 participants…

This phase 2 trial tests a personalized therapy called LN-145, made from a patient's own tumor-fighting immune cells. Researchers take a sample of the tumor, grow the immune cells in a lab, and then infuse them back into the patient after a short course of chemotherapy. The goal …

This study tests whether starting non-invasive ventilation (a breathing machine) earlier than usual helps people with ALS. Researchers will use a prediction tool to find those at high risk of breathing problems within 6 months. 48 participants will be randomly assigned to early N…

This early-stage trial tests gilteritinib, a drug already approved for leukemia, in 30 people with stage IV ALK-positive non-small cell lung cancer that has stopped responding to other treatments. The main goal is to find the safest dose and check for side effects. Researchers ho…

This study tests a new drug, BAY 3713372, for people with solid tumors that have a specific genetic deletion called MTAP. The drug is designed to kill cancer cells while sparing normal cells. The trial will first find a safe dose, then test how well it works in up to 450 particip…

This early-phase trial is testing a drug called tarlatamab, given as a shot under the skin, for people with extensive stage small cell lung cancer that has worsened after standard chemotherapy. The main goals are to check safety and side effects, and to see how the drug behaves i…

This phase 3 trial tests TAK-928, a drug designed to activate T cells inside tumors, against standard chemotherapy (docetaxel) in 600 adults with advanced non-small cell lung cancer that has worsened after prior treatments. The goal is to see if TAK-928 can shrink tumors or help …

This early-stage trial tests a new oral drug called ERAS-0015, alone or with other cancer drugs, in 600 adults with advanced solid tumors that have certain RAS mutations. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Researc…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This Phase 3 trial is testing whether adding an experimental drug called calderasib (MK-1084) to standard immunotherapy (pembrolizumab) can keep non-small cell lung cancer from returning after surgery. The study enrolls 400 people with a specific KRAS G12C mutation whose cancer w…

This phase 2b trial tests an oral drug called zipalertinib in 220 people with advanced non-small cell lung cancer that has certain EGFR mutations. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the drug daily, and researchers will monitor t…

This study tests whether adding a spacer device to standard triple inhaler therapy can reduce serious flare-ups in older adults (65+) with asthma or COPD who are at high risk. 380 participants will either use the spacer with their inhaler or stick with the inhaler alone. The goal…

This study is testing the safety of an inhaled dry powder form of treprostinil (LIQ861) for people with pulmonary hypertension (high blood pressure in the lungs) due to lung disease. About 80 adults will take the drug using a special inhaler, and researchers will monitor for side…

This phase 2 trial is testing whether giving the immunotherapy drug pembrolizumab (Keytruda) along with chemotherapy before surgery can eliminate all signs of cancer in people with resectable stage II to IIIB non-small cell lung cancer. About 60 participants will receive the comb…

This phase 3 trial tests whether adding the targeted pill calderasib (MK-1084) to the immunotherapy durvalumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 310 participants who have finished chemotherapy and radiation …

This phase 2 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy after surgery can help prevent small cell lung cancer from coming back. About 65 adults who had their cancer completely removed will receive the combination for 12 weeks, then durva…

This study tests a new device that uses microwave energy to destroy lung tumors during a bronchoscopy, before the patient has surgery to remove the tumor. The goal is to see if the device is safe and works well in 30 people with confirmed lung cancer who are already scheduled for…

This study tests whether a single dose of an experimental immune cell therapy called agenT-797, given alongside standard care, can lower the risk of death in adults with severe pneumonia and breathing failure. About 90 people in intensive care will receive either agenT-797 or a p…

This early-phase study tests gilteritinib, a drug already approved for a type of leukemia, in about 40 adults with ALK-positive non-small cell lung cancer whose tumors no longer respond to standard ALK inhibitors. Participants take gilteritinib tablets daily in 28-day cycles. The…

This phase 3 trial compares a new drug called pumitamig to the standard drug pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1 (at least 50%). The study will enroll 750 participants and measure ho…

This study tests whether adding a new drug called navlimetostat to standard immunotherapy (pembrolizumab) and chemotherapy helps people with a specific genetic form of advanced lung cancer (MTAP deletion) live longer without their cancer worsening. About 590 participants will be …

This Phase 3 trial is testing whether a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) can reduce serious heart and lung events in people with COPD who are at elevated risk. About 5,250 participants aged 40–80 will receive either the triple therapy or a d…

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…

This study tests whether a special radiation method (SFRT) given alongside immunotherapy (tislelizumab) and standard chemotherapy can shrink stage III lung tumors that cannot be surgically removed. The goal is to see if this combination makes more patients eligible for surgery. T…

This study tests whether a single dose of tocilizumab, an anti-inflammatory drug, can help children and adults with sickle cell disease recover faster from acute chest syndrome—a serious lung condition. Participants receive either the drug or a placebo, and researchers measure ho…

This early-stage trial tests a new oral drug called AMG 410, alone or with other medicines, in adults with advanced solid tumors that have KRAS gene changes. The study aims to find a safe dose and check for side effects. About 434 participants will take part across multiple dose …

This early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatme…

This study looks at whether the immunotherapy drug durvalumab can help people with limited-stage small-cell lung cancer when given after chemoradiation. Researchers will track 200 patients in China to see how long the cancer stays under control and how safe the treatment is. The …

This early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor…

This phase 2 trial tests whether adding tafolecimab (a cholesterol-lowering drug) to standard chemotherapy and the immunotherapy sintilimab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 40 adults who have not had prior tr…

This program offers early access to the investigational drug neladalkib for people with advanced ALK-positive lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial. Participants must be at least 18 years old…

This study tests a new drug called GEn-1124 in 52 adults with acute respiratory distress syndrome (ARDS), a severe lung condition. The drug is given as an IV infusion twice daily for 5 days, starting as soon as possible after diagnosis. The main goal is to check if the drug is sa…

This early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…

This phase III trial tests whether proton craniospinal irradiation (pCSI) can improve survival compared to standard involved-field radiation therapy (IFRT) for patients with breast or non-small cell lung cancer that has spread to the lining of the brain and spinal cord (leptomeni…

This phase 2 trial tests BI 764532 (obrixtamig), an antibody-like drug designed to help the immune system attack cancer cells. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to prior treatments. The study compares two…

This study tests whether a new drug called SCTB41, when combined with chemotherapy, works better than the standard immunotherapy tislelizumab plus chemotherapy for people with advanced non-small cell lung cancer that has no targetable genetic mutations. The trial has two parts: a…

This study tests the long-term safety of the drug nerandomilast in people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). All 1,700 participants have already taken the drug in a previous study. They will take nerandomilast tablets for up to 1 yea…

This study tests a daily pill called BI 1291583 (Verducatib) in 1755 adults and teens with bronchiectasis, a lung condition causing frequent infections and coughing. Participants take either the drug or a placebo for up to 76 weeks. The main goal is to see if the drug reduces the…

This study is testing two experimental drugs, BNT324 and BNT327, together in people with advanced lung cancer that has spread or come back. BNT324 targets and delivers a toxin to cancer cells, while BNT327 helps the immune system attack tumors and cuts off their blood supply. The…

This phase IIb study tests three doses of AZD8965 against a placebo in 359 adults with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. The main goal is to see if AZD8965 can slow the decline in lung function over 24 weeks. Participants may also be taking standard IP…

This study tests whether giving caffeine citrate to moderately preterm infants for 28 days after hospital discharge can prevent apnea (breathing pauses) that lead to sick visits. About 340 babies in Zambia will receive either caffeine or a placebo daily. Researchers will also che…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This study tests several new drug combinations, including pembrolizumab (an immunotherapy), with or without chemotherapy, in people with advanced non-small cell lung cancer who have not had prior treatment. The goal is to see if these combinations can shrink tumors and control th…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This study tests several drug combinations given before and after surgery for early-stage non-small cell lung cancer. About 630 participants will receive immunotherapy drugs like durvalumab along with chemotherapy or other targeted agents. The goal is to see if these combos can e…

This study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…

This Phase 3 study tests whether tezepelumab, a biologic drug, can reduce moderate to severe COPD flare-ups in adults aged 40-80. About 990 participants will receive either tezepelumab or a placebo as a shot under the skin. The main goal is to see if the drug lowers the number of…

This trial investigates whether specially engineered T cells can safely target and fight lung cancer. Participants have advanced or relapsed lung cancer and receive a single infusion of their own T cells that have been trained to recognize cancer-specific markers. The study aims …

This Phase 3 trial tests whether adding a wearable device that delivers electric fields (TTFields) to standard immunotherapy and chemotherapy improves survival in people with metastatic non-small cell lung cancer. About 734 participants who have not had prior treatment for their …

This phase 3 trial tests whether adding a precise, high-dose radiation treatment (SBRT) to standard chemoradiation and immunotherapy improves survival for people with locally advanced non-small cell lung cancer that cannot be surgically removed. About 474 participants will be ran…

This phase 3 trial is testing whether a combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of…

This early-stage trial is testing a new cell therapy called NEUK203-13 for people with advanced small cell lung cancer or other neuroendocrine tumors that have not responded to standard treatments. The therapy uses immune cells (NK cells) made from stem cells and engineered to ta…

This study tests a combination of two targeted drugs—sotorasib and trastuzumab deruxtecan—in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the combo works at shrinking tumors. About 37 …

This early-phase trial is testing a new drug called BMS-986517 in about 315 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug …

This early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…

This study compares two ways of placing Zephyr valves in the lungs of people with severe emphysema (a type of COPD). The standard method treats the entire lobe in one session, but about 27% of patients develop a collapsed lung (pneumothorax). The experimental method spreads the v…

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This Phase 2 study tests two new antibody-drug conjugates (R-DXd and I-DXd) against standard chemotherapy in 96 people with advanced nonsquamous non-small cell lung cancer that has worsened after prior immunotherapy and chemotherapy. These 'guided missiles' deliver a cancer-killi…

This early-stage trial is testing a new drug called JNJ-86974680, alone or with another drug (cetrelimab) and radiation, in people with advanced non-small cell lung cancer. The main goal is to find a safe and tolerable dose. About 126 participants will be enrolled. The study is c…

This study tests whether adding electro-acupuncture to standard first-line treatment (PD-1 inhibitors plus chemotherapy) helps people with metastatic non-small cell lung cancer. About 424 participants will receive either real or sham acupuncture alongside their cancer therapy. Th…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This phase 2 trial tests a combination of two drugs—lucankizumab and goleirex—as a first treatment for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study will enroll 43 participants to see if the combo shrinks tumors and how safe it …

This study tests a new medicine called BI 765423 in 71 adults with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. Participants receive either the drug or a placebo by infusion every four weeks for about 3 months. The main goal is …

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

This early-phase trial tests an experimental drug called RSC-1255, given alone or with hydroxychloroquine, in people with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The study has two parts: first, finding a safe dose, and …

This Phase 3 trial tests whether tezepelumab, a biologic drug given as a shot, can reduce the number of moderate to severe COPD flare-ups in adults aged 40 to 80. About 990 participants with moderate to very severe COPD will receive either tezepelumab or a placebo for up to 76 we…

This early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard…

This Phase 3 trial is testing a new oral drug called daraxonrasib (RMC-6236) against the standard chemotherapy docetaxel in about 590 people with advanced non-small cell lung cancer that has a specific RAS mutation. Participants must have already tried at least one prior treatmen…

This study tests whether the drug nerandomilast can slow lung scarring in people with autoimmune diseases like rheumatoid arthritis or scleroderma. About 400 adults whose lung function hasn't improved with standard treatment will take either nerandomilast or a placebo twice daily…

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This phase 3 trial tests whether adding the drug tarlatamab to standard chemotherapy and immunotherapy helps people with extensive-stage small-cell lung cancer live longer. About 330 participants will be randomly assigned to receive either the new combination or standard treatmen…

This Phase 2 trial tests whether a new drug called EL219 (Turletricin) is safe and effective for early treatment of invasive mould infections in people with weakened immune systems, such as those who have had a bone marrow transplant. About 60 participants will receive either EL2…

This study tests a new treatment called DJI136, which uses a patient's own immune cells engineered to target a protein (DLL3) found on small cell lung cancer cells. The trial enrolls 80 adults with extensive-stage small cell lung cancer whose disease has progressed after standard…

This phase 3 trial tests whether the drug sacituzumab govitecan (Trodelvy) helps people with extensive stage small cell lung cancer live longer compared to standard treatments. About 695 participants who have already had one round of chemotherapy will be randomly assigned to rece…

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…

This Phase 3 trial tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (Keytruda) can prevent non-small cell lung cancer from coming back after surgery. About 868 people with stage II-IIIB lung cancer who have had their tumors completely removed wil…

This phase 3 trial tests whether the immunotherapy drug cemiplimab can prevent lung cancer from returning after surgery in patients with stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 levels of 1% or higher. About 390 participants will either receive cem…

This study tests a new drug called izalontamab brengitecan against standard chemotherapy in 500 people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that has stopped responding to current targeted pills. The goal is to see if the new drug can delay…

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…

This study tests a drug called tarlatamab in people with advanced small cell lung cancer that has worsened after one prior treatment. About 48 participants will receive the drug by IV to see if it helps them live longer. The goal is to find a new option for patients who have limi…

This phase 3 trial tests whether adding the targeted drug adagrasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 630 adults who have not had …

This early-stage study is testing a new drug called calderasib (MK-1084) in people with advanced solid tumors that have a specific KRAS G12C mutation. The drug is given alone or combined with other cancer treatments. The main goals are to check safety and find the right dose. Abo…

This phase 3 trial tests whether a combination of an injected virus therapy (CAN-2409) and an immunotherapy drug (pembrolizumab) can help people with stage IV non-squamous non-small cell lung cancer live longer than standard chemotherapy. The virus is designed to kill tumor cells…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This study compares a nasal high-flow device to standard non-invasive ventilation (NIV) for treating people who come to the emergency room with a severe COPD flare-up and high carbon dioxide levels. Participants are randomly assigned to receive one of the two breathing supports f…

This phase II trial tests whether adding an experimental antibody called GT103 to the immunotherapy drug pembrolizumab can help people with advanced STK11-mutant non-small cell lung cancer. The study enrolls 28 adults whose cancer has worsened despite prior pembrolizumab treatmen…

This early study tests an experimental drug called XB010, alone or combined with the immunotherapy pembrolizumab, in people with advanced solid tumors (like lung, breast, or head and neck cancers) that have stopped responding to other treatments. The main goals are to find a safe…

This phase 2 trial is testing a new medicine called WIN378 for people with moderate to severe COPD. WIN378 is a long-acting antibody that blocks a protein involved in lung inflammation. The study will test different doses in 105 adults who are former smokers and already on standa…

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This early-stage trial is testing a new drug called GSK4527363 in healthy volunteers and people with active lupus or lupus-related lung disease. The main goal is to check safety and how the body handles the drug. Around 142 participants will take part across four groups, includin…

This phase II trial tests whether a radioactive drug called lutetium Lu 177 dotatate works better than the usual drug everolimus for people with advanced bronchial neuroendocrine tumors (a type of lung cancer). The radioactive drug targets a protein on tumor cells and delivers ra…

This early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. The main goals are to check safety and see if the drug shrinks tumors, given alone or with chemoth…

This phase 2 trial tests whether combining two drugs, SX-682 and pembrolizumab, can shrink tumors in people with advanced non-small cell lung cancer that has spread or come back. The study will enroll 30 adults whose tumors have a certain protein (PD-L1) and who have not had prio…

This study tests whether taking pentoxifylline and vitamin E during chemoradiation can prevent lung injury (pneumonitis) in stage III non-small cell lung cancer patients. 150 participants will receive either the drug combo or a placebo for 6 months. The goal is to see if this red…

This study tests a new targeted therapy called MK-1084, alone or combined with other drugs, in 190 people with advanced non-squamous non-small cell lung cancer that has a specific KRAS G12C mutation and has worsened after prior treatments. The main goals are to check safety and s…

This study tests whether adding AGuIX gadolinium-based nanoparticles to standard brain radiation can better control brain metastases that are at high risk of coming back. About 134 adults with certain cancers (like melanoma, lung, breast, or colorectal) that have spread to the br…

This study tests new combinations of cancer drugs in people with advanced or metastatic non-small cell lung cancer. The goal is to find safer and more effective treatments. About 152 participants will receive either novel drug pairs or new drugs plus standard therapy. The study f…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This study is for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the brain. Researchers want to see if adding a precise, one-time radiation treatment (SRS) to the standard drug osimertinib is better than the drug alone at controlling brain tumor…

This phase 3 study tests whether an inhaled drug called treprostinil can slow the worsening of lung function in people with progressive pulmonary fibrosis, a condition where lung scarring gets worse over time. About 698 adults will receive either the drug or a placebo four times …

This Phase 3 study tests whether adding olomorasib (a targeted pill) to standard immunotherapy (pembrolizumab or durvalumab) works better than immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer. The trial has two parts: one for patients whose cancer w…

This study tests if trilaciclib can protect bone marrow in people with limited-stage small cell lung cancer receiving chemotherapy. About 120 participants will get either trilaciclib or a placebo. The goal is to reduce severe low white blood cell counts and other complications fr…

This study is for people with a specific type of advanced lung cancer (EGFR L858R mutation). It tests a treatment plan that starts with a targeted drug (aumolertinib) alone for 6 weeks, then adds chemotherapy for 4 cycles, and finally continues with the targeted drug alone. The g…

This study tests an experimental drug called PF-07275315 in adults with moderate-to-severe COPD who have had at least two flare-ups in the past year. Participants receive either the drug or a placebo as injections over several months. The goal is to see if the drug improves lung …

This early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …

This early-phase trial is testing whether combining two drugs, lurbinectedin and osimertinib, is safe and effective for a rare type of lung cancer called transformed small cell lung cancer. The study will enroll 16 adults whose cancer has changed from a common form to this more a…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…

This global study is testing whether adding the experimental drug olomorasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C mutation). About 1,264 participants will receive either the ne…

This study compares two treatments after surgery for stage III-IVA head and neck cancer: radiation alone versus radiation plus the chemotherapy drug cisplatin. The goal is to see which approach better prevents the cancer from returning, especially in patients with certain TP53 ge…

This study tests a lower-dose radiation regimen for people with non-small cell lung cancer located near the center of the chest. The goal is to see if giving a total of 45 Gray in three sessions can control the tumor while reducing damage to nearby organs like the heart and major…

This trial investigates whether combining two targeted drugs, vebreltinib and furmonertinib, can control advanced non-small cell lung cancer in people whose tumors have both an EGFR mutation and high PD-L1 expression. The study enrolls about 45 adults who have not received prior …

This early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…

This phase 2 trial tests a combination of two drugs, ABSK043 and glecirasib, in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The study will enroll 86 participants to see if the combination is safe and can shrink tumors. It i…

This study tests an experimental drug called REGN5093 in people with advanced non-small cell lung cancer that has a specific change in the MET gene. The first part finds a safe dose, and the second part checks if the drug can shrink tumors. About 231 participants will take part.

This study tests a new way to manage blood thinning in patients on ECMO, a machine that helps the heart and lungs. The goal is to reduce bleeding and clotting problems, which affect over 40% of ECMO patients. Researchers will compare a combination of two blood thinners (nafamosta…

This study tests whether a focused ultrasound device can safely open the blood-brain barrier in people with non-small cell lung cancer that has spread to the brain. About 30 participants will receive standard immunotherapy plus the ultrasound procedure. The goal is to see if this…

This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…

This phase 2 trial is testing a type of radiation called craniospinal irradiation that avoids the hippocampus, a brain area key for memory. It is for people with breast or lung cancer that has spread to the fluid and lining around the brain and spinal cord. The goal is to see if …

This study is testing a device called the Indigo Aspiration System to remove blood clots from leg arteries in people with acute limb ischemia, a condition where a clot suddenly blocks blood flow. About 300 participants will undergo a procedure where the device sucks out the clot.…

This early-phase trial tests a new type of immunotherapy for people with a specific kind of advanced lung cancer (FRa-positive NSCLC). Researchers take a patient's own immune cells, engineer them to recognize and attack cancer cells, and deliver them directly into the chest cavit…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This study tests an experimental drug called SAR445399 in 70 adults aged 18-80 with non-cystic fibrosis bronchiectasis, a lung condition causing mucus buildup and infections. Participants receive either the drug or a placebo for 24 weeks to see if it reduces mucus plugs seen on C…

This phase 2 trial is testing whether adding two immunotherapy drugs, IPH5201 and durvalumab, to standard chemotherapy before and after surgery can improve outcomes for people with early-stage (stage II to III) non-small cell lung cancer. The study includes two groups: one receiv…

This early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …

This study tests a special balloon coated with the drug paclitaxel to treat benign (non-cancerous) narrowing of the windpipe or main breathing tubes. The balloon is inflated to open the airway, and the drug may help keep it open longer. About 200 adults with this condition will b…

This trial tests whether a special alert system called ICU Beacon can help doctors in intensive care units detect early signs of organ failure. The study includes about 1,962 adult ICU patients and compares units using the software plus standard care to those using standard care …

This study investigates whether a lower dose of two chemotherapy drugs (carboplatin and nab-paclitaxel) combined with a delayed dose of the immunotherapy serplulimab can effectively treat advanced squamous non-small cell lung cancer. The trial compares this gentler regimen to a s…

This study tests a new drug called IDE574 in people with advanced solid tumors or a specific type of breast cancer (ER+, HER2-). The drug targets two enzymes that help cancer cells grow. The study has two parts: first, testing IDE574 alone in various cancers; second, combining it…

This phase 2 trial is testing two experimental drugs, ubamatamab and REGN7075, alone or together, in 300 people with advanced or metastatic non-small cell lung cancer who have already had standard treatments. A third drug, sarilumab, may be used to manage immune-related side effe…

This study tests a new drug called YL201 combined with atezolizumab in people with advanced small cell lung cancer. The goal is to find safe doses and see if the combination helps control the disease. About 118 adults who have not had prior treatment for this cancer will take par…

This Phase 3 trial is testing a new oral drug, sevabertinib, against standard intravenous chemotherapy for people with advanced non-small cell lung cancer that has specific HER2 mutations. About 444 participants will be randomly assigned to receive either sevabertinib twice daily…

This study tests an experimental drug called recombinant human plasma gelsolin (rhu-pGSN) added to standard care for people with moderate-to-severe acute respiratory distress syndrome (ARDS) caused by pneumonia or other infections. About 600 hospitalized adults will receive eithe…

This study tests a new daily pill called TRI-611 for adults with advanced ALK-positive non-small cell lung cancer (NSCLC) that has not responded to other treatments. The trial has two parts: first, finding the safest dose, and second, seeing how well it shrinks tumors in differen…

This phase 2 trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery to people with stage III non-small cell lung cancer. The goal is to see if this approach can eliminate or greatly reduce the tumor before it is removed. The st…

This phase 3 study is testing whether adding an experimental pill called calderasib (MK-1084) to the immunotherapy drug pembrolizumab (Keytruda) works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and high PD-L1 …

This early-stage trial is testing a new drug called IM-1617 in people with advanced solid tumors (cancers that have spread or can't be removed by surgery). The study has two parts: first, finding a safe dose, then testing that dose in more people to see how well it works and how …

This study tests a new drug called lunsekimig in adults aged 40-80 with COPD that is not well controlled despite standard treatments. The goal is to see if the drug can reduce the number of moderate-to-severe flare-ups over 48 weeks compared to a placebo. Participants will receiv…

This study tests whether adding focused radiation or ablation to standard drug therapy can help people with lung cancer that has only a few new spots of growth. The goal is to see if this approach allows patients to stay on their current treatment longer without needing to switch…

This study compares a new drug, YL202, with the standard chemotherapy docetaxel in people with advanced non-small cell lung cancer that has a specific EGFR mutation. Participants must have already tried an EGFR-targeted therapy and platinum chemo without success. The goal is to s…

This study tests whether adding targeted radiation to immunotherapy can help control advanced non-small cell lung cancer better than standard chemotherapy. It is for patients whose cancer has worsened after previous immunotherapy. About 39 adults will be randomly assigned to one …

This Phase 2 trial is testing whether using two immune therapy drugs together with chemotherapy works better than one immune drug plus chemo for people with advanced non-small cell lung cancer that lacks the PD-L1 marker. Researchers will track changes in tumor DNA in the blood t…

This study tests whether a daily pill called zongertinib can help prevent lung cancer from coming back in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. All participants have had surgery to remove their tumor and standard che…

This early-stage trial is testing a new drug called AB821 in 50 adults with advanced melanoma or other solid tumors that respond to immune therapies. The main goal is to check safety and find the right dose. Participants receive AB821 by IV every 2 or 3 weeks for up to two years.

This early-stage trial is testing whether giving durvalumab as a shot under the skin works as well as the standard IV infusion. About 40 adults with various solid tumours will receive the injection, and researchers will measure drug levels in the blood and watch for side effects.…

This expanded access program provides the investigational drug zidesamtinib (NVL-520) to adults with advanced ROS1-positive non-small cell lung cancer or other solid tumors who have no satisfactory treatment options and cannot join a clinical trial. Participants must have receive…

This study tests a new medicine called fosmanogepix for adults with serious mold infections that are hard to treat. About 234 people will join, receiving either the new drug or standard care. The main goal is to see if fewer people die by day 42. The study is currently recruiting…

This Phase 3 trial is testing whether a combination of two drugs, datopotamab deruxtecan (Dato-DXd) and rilvegostomig, works better than the current standard treatment pembrolizumab for people with advanced non-squamous lung cancer that has high PD-L1 levels. About 675 participan…

This early study tests a new device that places tiny radioactive seeds directly into lung tumors that have come back after previous treatment. The seeds release a special type of radiation that spreads through the tumor. The goal is to see if the procedure is safe and possible in…

This study tests a new injectable drug called lunsekimig in about 942 adults aged 40-80 with COPD that is not well controlled, especially those with a type linked to high eosinophils (a kind of white blood cell). Participants will receive either the drug or a placebo for about 48…

This study tests a drug called divarasib, either alone or with other cancer treatments, in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the drug is safe and works to shrink or control the cancer. About 320 people who have …

This study tests the drug durvalumab as a consolidation (follow-up) treatment for people with limited-stage small cell lung cancer whose cancer has not grown after chemoradiation. About 70 participants in Spain will receive durvalumab every 4 weeks for up to 24 months. The goal i…

This study tests a drug called repotrectinib in 30 frail or elderly patients with advanced lung cancer that has a specific genetic change (ROS1). The goal is to see if the drug can shrink tumors or stop them from growing. Participants take the drug by mouth, and doctors monitor t…

This study tests a new inhaled powder called HSK39004 in 376 adults with COPD, a long-term lung disease that makes breathing hard. Participants will use the powder daily for 12 weeks to see if it improves lung function compared to a placebo. The goal is to control symptoms and he…

This Phase 3 trial tests whether adding the targeted drug calderasib to the immunotherapy pembrolizumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 675 participants with advanced non-squamous non-small cell lung cance…

This study tests whether combining two drugs, tepotinib and ivonescimab, is safe and works for people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. About 16 participants will try different doses to find the one with the fewes…

This study looks at whether placing a small tube through the chest wall to drain pus from a lung abscess, along with standard antibiotics, helps people recover faster and leave the hospital earlier. About 84 adults with large abscesses will be randomly assigned to get either the …

This early-phase trial is testing a new treatment called MEM-288, a virus designed to infect and kill cancer cells while also boosting the immune system. The study involves 40 adults with advanced solid tumors, including lung, skin, and breast cancers, who have not responded to s…

This study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …

This phase 2 trial tests whether MTX-463, an antibody that blocks a protein linked to scarring, can slow lung function decline in people with idiopathic pulmonary fibrosis (IPF). About 164 adults with IPF will receive either the drug or a placebo for 24 weeks. The main goal is to…

This study tests whether adding the experimental drug TRC102 to standard treatment (chemotherapy, radiation, and immunotherapy) can help shrink tumors and extend survival in people with stage III non-squamous lung cancer. TRC102 blocks cancer cells from repairing damage, making t…

This study tests a new experimental drug called PLX-61639 for people with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken as a daily pill and aims to shrink or control the cancer. A…

This early-stage trial is testing a new type of immune cell therapy for people with advanced cancers that have a specific protein called KK-LC-1. The cancers being studied include stomach, breast, cervical, and lung cancer. Participants will receive chemotherapy followed by a sin…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…

This early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, sto…

This study offers continued access to the inhaled drug TPIP for people with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (PH-ILD) who have already completed a related study. Participants must have successfully finished prior …

This phase 2 trial tests whether the drug belumosudil can help people who develop bronchiolitis obliterans syndrome (BOS), a type of lung scarring, after a stem cell transplant. The study will enroll 45 participants with new or early-stage BOS. Participants will take belumosudil …

This trial tests whether adding rituximab to standard mycophenolate mofetil (MMF) therapy can improve lung function in people with severe lung scarring caused by systemic sclerosis. About 102 adults with this condition will receive either rituximab infusions plus MMF or placebo i…

This early-phase trial is testing a new drug called HDM2020 in 150 people with advanced squamous non-small cell lung cancer. The drug is designed to target a protein on cancer cells and deliver a chemotherapy agent directly to them. The main goals are to check if the drug is safe…

This study tests a new drug called AZD3470 in people with advanced solid tumors that lack a gene called MTAP. The drug works by blocking a protein that cancer cells need to grow. The trial will check if the drug is safe, tolerable, and effective, both alone and with other cancer …

This rollover study allows up to 40 people with KRAS G12C-mutated lung or other solid tumors who are already benefiting from opnurasib in a Novartis trial to keep receiving the drug. Participants continue their current dose of opnurasib alone or with TNO155 or trametinib. The goa…

This early-phase study tests a new drug, ASP2998, that targets a protein called TROP2 found on many solid tumors. The drug is given alone or with standard treatments like pembrolizumab or carboplatin. The main goals are to check safety and find the right dose. About 428 adults wi…

This Phase 2 trial tests whether rademikibart, an injected drug, can help adults with COPD who are having a sudden flare-up and have a specific type of inflammation (type 2). The study will compare the drug to a placebo in 160 participants, looking at whether it reduces treatment…

This phase II trial is testing the drug osimertinib in 46 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants will take osimertinib …

This study tests whether dupilumab, an injectable drug, can reduce mucus plugs (blockages) in the lungs of people with moderate-to-severe COPD. About 218 current or former smokers aged 40-85 will receive either dupilumab or a placebo for 24 weeks. The main goal is to see if the d…

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…

This study aims to create and test a clinical prediction score called FUNGAL-P to help doctors identify fungal pneumonia early in adults who come to the hospital with pneumonia. Researchers will analyze medical records from past patients and then test the score on new patients to…

This study tests whether an artificial intelligence (AI) tool that analyzes a simple ECG can help doctors find undiagnosed pulmonary hypertension (high blood pressure in the lungs) in people with interstitial lung disease. About 900 adults with severe lung scarring will be random…

This study will test a handheld ultrasonic spirometer against a conventional hospital spirometer in 100 adults with chronic respiratory diseases like COPD or asthma. Each participant will use both devices to see if the portable one gives accurate and reliable results. If successf…

This study tests whether using a lung ultrasound score can help doctors decide when to give surfactant therapy to premature infants with respiratory distress syndrome. Surfactant is a substance that helps babies' lungs stay open, but giving it too late can reduce its benefit. The…

This study is testing a new blood test called EXoPred that uses artificial intelligence and laser technology to find tiny particles from cancer cells. The goal is to detect breast, colon, pancreatic, ovarian, and lung cancers at an early stage. Researchers will enroll 1,400 peopl…

This study tests a new type of PET/CT scan that looks for a protein called DLL3 on small cell lung cancer cells. The goal is to see if this scan can find tumors more clearly than standard imaging methods like CT or regular PET scans. About 20 adults with suspected or confirmed sm…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This early-phase study is testing two radioactive imaging agents, 68Ga-DFC413 and 68Ga-NNS309, to see how well they highlight tumors on PET scans. About 66 adults with advanced pancreatic, lung, breast, colorectal, or soft tissue cancers will receive the agents. The goal is to co…

This study tests a new radioactive tracer called 89Zr-DFO-SC16.56 that attaches to a protein called DLL3 found on small cell lung cancer cells. The goal is to see if PET scans using this tracer can safely and accurately show where the cancer is in the body. About 53 adults with s…

This study is testing a new way to check the health of ICU patients who are on breathing machines. Researchers collect a small sample of the air patients breathe out and analyze its proteins. They also take a blood sample to look for related changes in DNA, RNA, and other molecul…

This early-stage trial tests a radioactive imaging agent called [111In]-FPI-2107 in 12 Chinese adults with EGFR-mutant non-small cell lung cancer. The goal is to see if it is safe and can help detect tumors on SPECT scans. Participants receive the agent plus an unlabelled antibod…

This study is testing a lung cancer screening program for smokers aged 45 to 74. It uses low-dose CT scans and metabolomics to find lung nodules and reduce false negatives. The goal is to improve early detection and help smokers quit. 1,000 participants will be followed in a publ…

This study is testing a new radioactive probe called PFD3, used with a PET/CT scan, to see if it can better find and assess small cell lung cancer (SCLC) by targeting a protein called DLL3 found on cancer cells. About 30 adults with SCLC will receive both a standard FDG scan and …

This study enrolls 1000 people with untreated non-small cell lung cancer to compare different genetic tests for MET gene changes. Participants provide tumor samples for testing, and researchers check how well the tests agree. The goal is to improve diagnosis and guide treatment c…

This study looks at whether community pharmacists can help more people get screened for lung cancer. It will enroll 300 adults aged 50-77 who are current or former heavy smokers. Participants can choose a simple blood test or a CT scan to check for early signs of lung cancer. The…

Lung cancer is the top cancer killer of Veterans, often found too late to cure. This trial tests whether giving doctors personalized prediction tools and dashboards can increase lung cancer screening rates among 23,520 high-risk Veterans. The goal is to catch cancer earlier and r…

This study tests a drug called nerandomilast in 80 people aged 40+ who have early lung changes and a family history of pulmonary fibrosis. Participants take either the drug or a placebo twice daily for up to 3 years. Doctors monitor lung function and scans to see if the drug slow…

This study tests whether the drug canakinumab can prevent lung cancer in 50 people who have suspicious lung nodules that haven't gone away. Participants receive the drug and are monitored for nodule shrinkage and cancer development. The goal is to see if this approach can stop lu…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study tests whether yoga and mindfulness programs can improve quality of life, reduce inflammation, and even affect gene activity in people who have survived lung, colon, or non-Hodgkin's lymphoma cancer. One hundred survivors, at least six months past treatment, will be ran…

This study investigates whether drinking nitrate-rich beetroot juice twice a day for three days can improve exercise capacity in people with idiopathic pulmonary fibrosis (IPF), a lung scarring disease that limits activity. Researchers will compare the juice to a placebo in a sma…

This trial tests whether giving the painkiller parecoxib before a CT-guided wire placement can reduce pain during lung nodule localization for surgery. About 150 adults with lung cancer scheduled for video-assisted thoracoscopic surgery will receive either parecoxib or a placebo …

This study tests whether freezing certain nerves during minimally invasive lung surgery can help patients recover faster with less pain. 150 adults having lung surgery will either get standard pain management or standard care plus nerve freezing. The goal is to see if the freezin…

This study tests whether personalized follow-up with a sport-health professional helps people with chronic respiratory diseases maintain the benefits of pulmonary rehabilitation. 352 participants will either receive tailored support or usual care. The main goal is to see if those…

This study tests whether a single 20-minute session with a medical device called Simeox can reduce the amount of air trapped in the lungs of people with severe COPD. The device applies gentle suction during exhalation to help move air out. Researchers will measure lung function b…

This study tests whether a home-based aerobic exercise program can help lung cancer patients respond better to immunotherapy. Researchers will measure changes in immune cells and inflammation markers in 100 participants. The goal is to see if exercise can improve treatment effect…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

This study tests an oral drug called vapendavir in 180 adults with COPD who catch a rhinovirus (common cold). The goal is to see if it can reduce the severity and length of breathing symptoms compared to a placebo. Participants are randomly assigned to one of two doses or a place…

This study tests whether combining arm and leg endurance training is better than leg training alone for improving daily activities in people with COPD. 36 participants with moderate-to-severe COPD will undergo 14 supervised sessions. The main goal is to see if the combined traini…

This study tests whether a device called Airvo 3, which automatically adjusts oxygen levels, can keep COPD patients' blood oxygen in a healthy range better than manual adjustments by nurses. About 70 hospitalized adults with COPD and low oxygen will take part. The goal is to see …

This study tests whether acupuncture at specific points before and after lung cancer surgery can improve sleep and reduce long-term pain. About 316 patients will receive either real or sham acupuncture alongside standard care. The goal is to see if this simple, low-risk treatment…

This study looks at whether using a nasal high-flow device (which delivers warm, moist air at a high rate) can help people with COPD walk farther during a 6-minute walk test. Thirty adults with COPD will try both the high-flow device and a standard low-flow device on different da…

This pilot study tests a self-management program based on cognitive behavioral therapy to help people who survived acute respiratory failure and now struggle with anxiety. Sixty ICU survivors will either receive the program or usual care. The goal is to see if the program is prac…

This study tests whether a therapy called Meaning-Centered Psychotherapy for Latinos (MCP-L) can help reduce anxiety and depression in 300 Latino patients with advanced cancer. Participants receive either MCP-L or standard cognitive behavioral therapy over about 3 months. The goa…

This Phase 2 trial tests a drug called ASCA101 in 135 adults with solid tumors (colorectal, ovarian, or lung cancer) who have cachexia—a condition causing severe weight loss and muscle wasting. Participants receive either ASCA101, an active control (Megace), or a placebo for 12 w…

This study tests whether a respiratory rehabilitation program—including exercise training, breathing exercises, and education—can improve quality of life for people with advanced non-small cell lung cancer who are on maintenance chemotherapy and immunotherapy. Researchers will co…

This study tests a new program called Mindful-Breath for people with chronic obstructive pulmonary disease (COPD). The program combines mindfulness, breathing exercises, and lifestyle coaching through group sessions and chat support. Researchers want to see if it is feasible and …

This study looks at whether people with COPD and chronic bronchitis who switch from regular cigarettes to a tobacco heating system feel better and breathe easier. About 290 adults aged 40 and older who have smoked for at least 10 years will take part. Researchers will measure cou…

This study tests whether a prehabilitation program that combines home and center-based exercise works as well as a center-only program for people about to have lung cancer surgery. 38 adults with non-small cell lung cancer will be randomly assigned to either 15 sessions at the ce…

This study tests whether using a mobile app that gives visual feedback can help lung cancer patients do breathing exercises more effectively after having part of a lung removed. Forty patients will try both standard breathing training and app-guided training on the same day. Rese…

This study is testing whether the immunotherapy drug pembrolizumab can improve quality of life for people with advanced non-small cell lung cancer who are not healthy enough for standard treatments. The trial will enroll 45 patients who have not had prior cancer therapy and have …

This study pools data from multiple countries to see how a triple-combination inhaler (BGF) affects the daily lives of 2,000 people with moderate to severe COPD. Researchers will compare health status scores at 1, 3, and 12 months after starting treatment. The goal is to understa…

This study tests whether using a video camera (video laryngoscopy) helps doctors give surfactant—a medicine that helps lungs work—to very premature babies more successfully on the first try compared to the standard direct-look method. About 100 babies born at 28 weeks or earlier …

This study tests a navigation program for cancer patients starting immunotherapy. The program helps with essential needs like food, transportation, and housing, and tracks side effects. Researchers want to see if this support helps patients continue their treatment and improves t…

This study tests whether inhaling a salty mist (3% hypertonic saline) can improve breathing symptoms in people with nontuberculous mycobacterial (NTM) lung disease who haven't yet started antibiotics. About 262 adults will either start the saltwater treatment right away for 6 mon…

This study tests a new tool called the Buckeye Quit Stick to help smokers with lung cancer quit. The stick replaces the hand-to-mouth habit of smoking without using medicine. About 30 adults will try it for 6 months to see if it helps them stay smoke-free.

This study aims to learn more about Hyper IgE syndrome, a rare immune disorder that causes skin and lung infections. Researchers will follow 600 patients and their relatives over time, examining their health and genetics. The goal is to better understand the disease and improve c…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This natural history study follows 270 adults with pulmonary arterial hypertension (PAH) and healthy volunteers to track how the disease changes over time. Researchers will use blood tests, heart and lung imaging, and a six-minute walk test to find new markers of disease severity…

This study aims to collect tumor, normal tissue, and blood samples from up to 1559 people with cancers of the lung, esophagus, or pleura. Researchers will analyze genetic and epigenetic changes to better understand these diseases and identify potential markers for future treatmen…

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…

This study tests whether bundling key tests like scans and lung function tests into a single, fast-tracked appointment can help people with suspected interstitial lung disease get a diagnosis sooner. About 92 adults will be randomly assigned to either the usual step-by-step testi…

This study aims to learn more about Hermansky-Pudlak Syndrome (HPS), a rare inherited disease that causes light skin/eye color, bleeding problems, and often deadly lung scarring. Researchers will follow 600 people with HPS and their family members to track how the disease progres…

This study follows people with a rare genetic condition called DICER1 syndrome, which raises the risk of certain childhood cancers like pleuropulmonary blastoma. Researchers will collect medical histories, genetic samples, and tissue from up to 1,500 participants and their relati…

This study follows 900 people with bronchiectasis—a condition where airways are damaged and prone to infection—to learn why they get sick repeatedly. Researchers will collect medical history, lung function tests, and blood, urine, and sputum samples from patients and their family…

This study aims to develop a better way to remotely monitor people with chronic respiratory failure who use a breathing machine (noninvasive ventilation) at home. Researchers will collect data from standard monitoring tools and new non-invasive devices to assess breathing, lung f…

This study follows up to 3,500 people with sickle cell disease to learn more about how the condition progresses and what complications arise. Participants receive their usual medical care outside the hospital and visit the clinic for check-ups and research tests. No experimental …

This study tests a new AI system called IntelliLung that suggests ventilator settings for ICU patients on breathing machines. Researchers will compare how often doctors' settings match the AI's recommendations. About 530 adults on ventilators will take part across multiple hospit…

This study is testing a web-based tool called CARE that gives cancer patients information about treatment costs, health insurance, and financial resources. About 430 adults with gynecologic, prostate, lung, or colorectal cancer will use the tool to see if it helps them feel more …

This study looks at how mucus plugs in the lungs affect breathing in people with severe asthma. Researchers will use special MRI scans to see air flow in blocked areas. Only 5 adults with severe asthma will take part, and the goal is to better understand lung function, not to tes…

This study collects blood and tumor tissue samples from people with head and neck or lung cancers to find biological markers that indicate low oxygen levels within tumors. Low-oxygen tumors tend to be more aggressive and resistant to standard treatments like radiation and chemoth…

This study looks at 50 children (over 1 year old) in intensive care who are on breathing machines due to acute respiratory distress syndrome (ARDS). Researchers want to see if two methods can reliably measure airway opening pressure, which could help doctors personalize ventilati…

This study is looking for genetic clues that might tell doctors whether immunotherapy will work well before lung cancer surgery. Researchers will collect blood and tumor samples from 100 people with stage II-IIIB non-small cell lung cancer. They will test for two types of genetic…

This study looks at preterm infants who need breathing support from a machine called nasal CPAP. Researchers want to find out how much oxygen actually reaches the baby's lungs by placing a small tube in the back of the mouth and using soft bands around the chest to measure lung e…

This study collects tissue samples and health information from 2000 adults with certain lung and thymic cancers. Researchers aim to better understand these diseases, which could lead to new diagnostic tools and treatments. Participants provide blood, tumor samples, and imaging da…

This study is observing how well the Ion endoluminal system, a robotic tool, works for lung nodule biopsies and localization in everyday medical practice across Europe. Researchers will track 1,200 adults to see how often the tool correctly diagnoses lung nodules and how often co…

This study tests whether a live video connection between paramedics and pediatric emergency doctors improves care for critically ill children. Paramedics will treat infant mannequins in simulated ambulance scenarios, with some getting video support and others only audio. The goal…

This study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …

This study aims to learn more about diseases that affect the salivary glands, which produce saliva. Researchers will collect medical data, blood, saliva, and tissue samples from people with these conditions, their relatives, and healthy volunteers. The goal is to better understan…

This study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study is collecting live tumor samples from 2,000 cancer patients undergoing standard biopsies. Researchers will analyze these samples to understand how tumors respond to immunotherapy drugs outside the body. The goal is to develop a method to predict which patients will res…

This study observes 500 Spanish patients with EGFR-mutated non-small cell lung cancer who are taking osimertinib in routine care. It aims to measure survival, quality of life, and how long patients stay on treatment. The goal is to see if results from clinical trials hold up in r…

This study observes 600 adult patients after major surgery to see if simple bedside tests—like ultrasound of breathing muscles and a breathing score—can predict who will need a breathing tube again. No new treatments are given; doctors make all decisions as usual. The goal is to …

This study tests whether combining 4D MRI and 4D CT scans can better track lung tumors and nearby organs as a person breathes during radiation therapy. Researchers will compare this new method to the current standard. The goal is to see if it improves targeting of the tumor while…

This study tests whether giving oxygen to the lung that is not being ventilated during lung cancer surgery can reduce inflammation and improve oxygen levels. Researchers will measure inflammatory markers in lung tissue and blood from 56 adult patients. The goal is to see if this …

This study is a disease registry that will follow about 700 people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. Researchers will collect information on patient characteristics, treatments, and outcomes over time to better un…

This study tests a short, 10-15 minute health assessment called the Practical Geriatric Assessment (PGA) for adults aged 65 and older with early-stage non-small cell lung cancer who are about to receive radiation therapy. The goal is to see if using this quick checkup leads to mo…

This study watches for heart changes in 150 adults receiving chest radiation for lung, esophageal, breast, or thymus cancer. Researchers will check heart markers, electrical activity, and immune cells at the end of treatment and up to 3 months later. The goal is to find early sig…

This study tests a low-literacy conversation tool designed to help lung cancer patients and their doctors make treatment decisions together. Researchers will enroll 300 patients to see if the tool improves understanding, reduces confusion, and boosts confidence in choices. The fo…

This study follows 500 European patients with advanced non-small cell lung cancer who are already prescribed cemiplimab (Libtayo) as part of their normal care. Researchers will track how long patients live, how well the cancer responds, and any side effects. The goal is to see if…

This study looks at whether testing lung cancer cells in a lab can predict which drugs will work best for each patient. Researchers will collect fluid from around the lungs of 400 people with lung cancer who need drainage for shortness of breath. They will grow the cancer cells i…

This study looks back at 600 advanced lung cancer patients who received immunotherapy. Researchers will analyze their tissue samples and genetic data to find patterns linked to long-term survival. They aim to build an AI model that can predict survival from standard microscope im…

This study looks at how well people with COPD understand health information and how that relates to their physical abilities, thinking skills, daily activities, and quality of life. Researchers will compare 144 adults with COPD to healthy volunteers using tests of walking, thinki…

This study compares two types of CPAP machines that help premature babies breathe. One delivers a constant flow of air, the other a variable flow. Researchers will measure the babies' diaphragm activity to see if constant flow works just as well. The study involves 20 infants bor…

This study is tracking how the cancer drug tislelizumab is actually used in everyday European clinics for patients with advanced non-small cell or small cell lung cancer. Researchers will observe 440 participants to see treatment patterns, dosing changes, and real-world outcomes …

This study looks at when to perform a lung recruitment maneuver—a procedure that reopens collapsed lung areas—during robotic prostate surgery. Researchers will compare doing it before or after the patient is tilted head-down and gas is pumped into the abdomen. The goal is to see …

This study looks at 100 adults aged 65 and older with fibrosing interstitial lung disease, a condition that scars the lungs and shortens life. Researchers will assess frailty and muscle loss (sarcopenia) using questionnaires and tests to see if these factors predict hospital stay…

This study looks at fluid from around the lungs (pleural effusion) in people with non-small cell lung cancer. Researchers want to see how often important cancer markers like PD-L1, ALK, and EGFR can be found in that fluid. They will also check if the amount of fluid tested affect…

This study looks at whether giving extra oxygen during a 6-minute walk test helps people with chronic lung disease walk farther and feel better. About 114 adults with conditions like COPD or interstitial lung disease will do two walking tests—one with their usual oxygen and one w…

This study aims to learn more about non-tuberculous mycobacterial (NTM) infections, which cause repeated lung and other organ infections. Researchers will study up to 1,000 participants to understand the genetics, symptoms, and best treatments for these infections. The study also…

This study aims to understand how lymphangioleiomyomatosis (LAM) damages the lungs at the cellular and genetic level. Researchers will follow up to 2,000 participants, including women with LAM and healthy volunteers, using advanced imaging and lab tests. The goal is to find the p…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …

This large study is testing many different drug combinations, including the immunotherapy pembrolizumab, in people with advanced non-small cell lung cancer. The goal is to see which treatments work best based on specific tumor features like PD-L1 levels and histology. Over 1,000 …

This observational study compares how people with bronchiectasis and healthy volunteers respond to different exercise tests, including a 6-minute stepper test, a 6-minute walk test, and a 1-minute sit-to-stand test. Researchers will measure breathing, heart rate, and muscle stren…

This pilot study tests whether using a lower breathing rate on ventilators is safe and practical for critically ill patients. About 56 adults on breathing machines will be randomly assigned to either the new lower-rate approach or standard care. The goal is to see if the new meth…

This study looks at whether a program called 'Couples Coping Together Against Cancer' is helpful and practical for people with advanced cancers like stage IV breast cancer, glioblastoma, or lung cancer, and their partners. Researchers at City of Hope will enroll 160 couples to se…

This study is collecting tumor tissue and blood samples from 800 people with lung cancer to look for changes in a gene pathway called EGFR. The goal is to better understand the DNA mutations that drive the disease. No new treatment is being tested; instead, researchers hope to id…

This study reviews medical records of 250 adults in Brazil with advanced non-squamous non-small cell lung cancer whose cancer progressed after platinum-based chemotherapy. Researchers will describe patient characteristics, treatments used, and outcomes in routine practice. The go…

This study is testing whether a program that includes virtual pulmonary rehabilitation, integrated care, and remote monitoring using a smartwatch and home spirometer is feasible for people with COPD after a recent flare-up. Researchers will enroll 100 patients and track how many …

This study looks at proteins in lung fluid from 750 people with pneumonia to find biomarkers that could reveal what's causing the lung inflammation. Participants undergo a standard bronchoscopy with lung washings, plus a blood draw. The goal is to better understand different type…

This study follows 2,000 children who receive stem cell transplants to better understand and detect lung injuries that can occur after the procedure. Researchers will track participants for two years, collecting samples and health data to find ways to diagnose problems earlier. T…

This study at Mayo Clinic looks at how changes in the blood vessels of the lungs affect people with heart valve disease. Researchers will use echocardiograms during routine heart catheterization to measure these changes in 600 adults scheduled for valve procedures. The goal is to…

This study from Mayo Clinic is looking at how T cells (a type of immune cell) change during anti-PD-1 immunotherapy in people with advanced melanoma, lung cancer, or other solid tumors. Researchers will collect blood and tissue samples from 500 participants to measure specific ma…

This study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establis…

This study aims to understand why some people get severe or unusual fungal infections due to immune system problems. Researchers will collect blood, tissue, and other samples from up to 1,200 participants over 25 years. No new treatments are being tested; the goal is to learn mor…

This study looks at whether the natural variation in heartbeat timing (heart rate variability) can help doctors decide the right oxygen flow for patients with respiratory failure who are on a high-flow nasal cannula. Researchers will gradually lower the oxygen flow and monitor he…

This study looks at whether an artificial intelligence (AI) tool can predict if lung scarring (pulmonary fibrosis) will get worse over time. Researchers will analyze CT scans from 200 people with either idiopathic pulmonary fibrosis (IPF) or other types of interstitial lung disea…

This large study in Ohio is looking at whether advanced genomic testing and immunotherapy decision support can help people with stage IV non-small cell lung cancer live longer and have a better quality of life. Researchers will compare standard care with a more personalized appro…

This study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…

This study is observing 200 people with extensive stage small cell lung cancer to learn more about the genetic makeup of their tumors. Researchers will analyze tumor tissue and blood samples to see if certain genetic patterns are linked to how well treatments work. The goal is to…

This study reviews medical records of 500 Polynesian patients with bronchiectasis (widened airways) to understand why the condition is so common in French Polynesia. Researchers will look at age of onset, family history, infections, and CT scan patterns to see if a genetic cause …

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study looks at why immune cells in people with COPD don't work properly to clear bacteria from the lungs. Researchers will collect cells from the lungs and blood of 189 participants, including COPD patients and healthy smokers and non-smokers. They will study how these cells…

This study uses surveys to understand what factors influence Chinese patients and doctors when selecting first-line EGFR-TKI therapy for advanced non-small cell lung cancer. Researchers will ask about preferences for treatment benefits, side effects, and other attributes. The goa…

This study looks at two ways to manage pain in children having the Nuss procedure for pectus excavatum (a sunken chest). One group received standard nerve freezing (cryoanalgesia) alone, while the other also had a nerve block near the diaphragm. Researchers will compare pain scor…

This study is collecting information from 130 people with advanced EGFR-mutant non-small cell lung cancer who are starting treatment with osimertinib. Researchers want to see how long the drug controls the cancer in real-world settings, outside of strict clinical trial conditions…

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…

This study looks at whether a blood test called liquid biopsy can quickly find genetic changes in people with advanced lung cancer. About 70 adults will give a blood sample, and researchers will compare the results to standard tissue biopsies. The goal is to see if this approach …

This study collects exhaled breath from 240 adults—some with COPD and some without—to compare the types and amounts of bacteria present. Participants breathe through a straw into a device for 5 minutes, and a second sample is taken a year later. The goal is to understand how the …

This study looks at how genes play a role in lung diseases like cystic fibrosis, asthma, and pulmonary fibrosis. Researchers will examine DNA from up to 3,500 people with and without lung disease to find genetic differences. The goal is to better understand what causes these cond…

This study looks at 790 adults with S. maltophilia infections, a hard-to-treat bacteria. Researchers will compare patients who got one antibiotic versus those who got a combination, to see which group has fewer deaths within 30 days. The goal is to find the best treatment approac…

This study follows 320 Chinese adults with non-cystic fibrosis bronchiectasis (a chronic lung condition causing cough and infections) and some healthy volunteers for 12 months. Researchers will collect lung function tests, blood samples, and imaging to identify biomarkers and dis…

This study aims to understand why breathlessness varies among people with different lung diseases like COPD, asthma, and ILD. Researchers will measure lung function, exercise ability, and breathing patterns in 75 participants (50 with lung disease and 25 healthy controls). The go…

This study tests a program called CONNECTing to LungCare that helps smokers have better conversations with their doctors about quitting smoking and getting screened for lung cancer. The program includes educational materials and a personalized summary to guide discussions. Resear…

This study is collecting information from 650 people with advanced lung cancer to create 'control arms' — groups that help researchers compare how well new treatments work. Participants will receive standard therapies, and their outcomes will be tracked. The goal is to make futur…

This study looks at whether a substance in the blood called soluble PD-1 can help predict if a certain type of lung disease caused by NTM bacteria will get worse. Researchers will follow 500 adults from different countries to see if higher levels of this marker are linked to more…

This study will check 1,000 smokers aged 40+ who visit heart doctors to see how many have undiagnosed COPD, a lung disease that often goes unnoticed. Participants will take a simple breathing test and answer a questionnaire. The goal is to find out how common hidden COPD is in th…

This study is collecting information on side effects from proton therapy in 5,000 adults with many types of cancer. Researchers will track both short-term and long-term side effects and link them to the details of each patient's treatment plan. The goal is to better predict who m…

This study looks at whether stopping tube feeding for at least 8 hours before a procedure helps or harms recovery in critically ill patients on breathing machines. About 1,072 adults in the ICU will be randomly assigned to either fast or continue feeding until right before their …

This study looks at whether people with type 2 diabetes, COPD, or heart disease who join a health program in Halsnaes Municipality improve their physical function and well-being. About 194 adults will be tracked before and after the program using tests and questionnaires. The goa…

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study follows 650 adults who had pneumonia (including COVID-19) to see how the infection might lead to heart disease later. Researchers will collect blood samples, run heart and lung tests, and track heart attacks, strokes, and other events over three years. No new treatment…